Black Diamond Therapeutics (BDTX) to Release Quarterly Earnings on Monday

Black Diamond Therapeutics (NASDAQ:BDTX) is expected to release its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect Black Diamond Therapeutics to post earnings of ($0.18) per share and revenue of $25.00 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 15, 2026 at 4:00 PM ET.

Black Diamond Therapeutics (NASDAQ:BDTX) last issued its quarterly earnings results on Monday, March 16th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.04. On average, analysts expect Black Diamond Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Black Diamond Therapeutics Stock Up 3.3%

Black Diamond Therapeutics stock traded up $0.09 during midday trading on Monday, hitting $2.69. The company’s stock had a trading volume of 387,522 shares, compared to its average volume of 750,503. The stock’s 50-day moving average price is $2.46 and its 200-day moving average price is $2.86. Black Diamond Therapeutics has a 12 month low of $1.46 and a 12 month high of $4.94. The company has a market capitalization of $153.82 million, a PE ratio of 7.26 and a beta of 3.34.

Wall Street Analyst Weigh In

Several analysts have issued reports on BDTX shares. Jefferies Financial Group upgraded Black Diamond Therapeutics to a “strong-buy” rating in a report on Thursday, April 23rd. Wedbush boosted their price objective on Black Diamond Therapeutics from $13.00 to $14.00 and gave the stock an “outperform” rating in a report on Tuesday, March 17th. Piper Sandler cut their price objective on Black Diamond Therapeutics from $9.00 to $8.00 and set an “overweight” rating on the stock in a report on Friday, January 16th. BTIG Research lifted their target price on Black Diamond Therapeutics from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. Finally, Zacks Research cut Black Diamond Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Hedge Funds Weigh In On Black Diamond Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its stake in Black Diamond Therapeutics by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 505,780 shares of the company’s stock valued at $1,229,000 after acquiring an additional 5,257 shares during the last quarter. Engineers Gate Manager LP lifted its stake in Black Diamond Therapeutics by 48.9% in the fourth quarter. Engineers Gate Manager LP now owns 19,701 shares of the company’s stock valued at $48,000 after acquiring an additional 6,469 shares during the last quarter. Bank of America Corp DE lifted its stake in Black Diamond Therapeutics by 22.5% in the third quarter. Bank of America Corp DE now owns 43,359 shares of the company’s stock valued at $164,000 after acquiring an additional 7,972 shares during the last quarter. Cerity Partners LLC acquired a new stake in Black Diamond Therapeutics in the second quarter valued at approximately $26,000. Finally, Virtu Financial LLC acquired a new stake in Black Diamond Therapeutics in the third quarter valued at approximately $39,000. Institutional investors and hedge funds own 95.47% of the company’s stock.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc is a precision oncology company focused on the discovery and development of small-molecule therapies that selectively target oncogenic proteins bearing tumor-driving mutations. Leveraging its proprietary Genetic Defined Allosteric (GDA) therapeutic platform, the company aims to identify unique allosteric binding sites in mutant proteins and engineer highly selective inhibitors. Headquartered in Cambridge, Massachusetts, Black Diamond applies structure-based drug design and molecular modeling to advance personalized cancer treatments.

The company’s development pipeline includes lead candidate BDTX-189, an allosteric inhibitor of mutant HER2, as well as programs directed at clinically relevant EGFR and KRAS mutations.